Needham & Company Downgrades ResMed (RMD) to Hold

Needham & Company downgraded ResMed (NYSE: RMD) from Buy to Hold.

Analyst Mike Matson commented, "We expect RMD's revenue growth to slow significantly as it faces three headwinds during CY16: tough comps from the AirSense/AirCurve flow generator launch, increased competition from Respironics' new products, and additional Medicare reimbursement cuts. While we believe that these are accounted for in consensus estimates, we think there is a greater probability of downside than upside to estimates and we worry that slowing growth could drive P/E multiple compression. As a result, we are downgrading RMD to Hold."

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $56.13 yesterday.

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics